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Heart failure is a major health problem in the
developed countries with millions of affected pa-
tients and an increasing number of hospitalizations
and deaths attributed to this disease [1]. Significant
progress in our understanding of pathophysiology
of heart failure and development of new, effective
therapies helped lower morbidity and mortality of
this population. However, with the development of
each new therapy, the complexity of management
of heart failure is increasing, and a significant pro-
portion of patients with heart failure (HF) are not
receiving treatment with guideline-recommended,
evidence-based therapies. In this context the paper
by Fedyk-Łukasik in this issue of Cardiology Jour-
nal is very timely [2]. Although “score cards” are
usually not our favorite reading material, this care-
ful review of practice patterns in management of
heart failure in Poland documents trends in physi-
cians’ performance and gives guidance for improve-
ment. It definitely should be noted with satisfaction,
that high percentage of both inpatients (88%) and
outpatients (81%) with heart failure were treated
with angiotensin converting enzyme inhibitors
(ACE-I) and that high percentage of outpatients
were treated with beta-blockers (84.7%). These
efforts provide patients with tremendous survival
advantage as demonstrated by Cohn in the analysis
of placebo arm of Val-HeFT (the Valsartan Heart
Failure Trial). Overall mortality over 23 months of
follow up in this trial was 31.6% in patients who did
not receive ACE-I and beta blockers and 11.9% in
patients receiving both ACE-I and beta-blockers.
This means that there was a 62% reduction of mor-
tality with combined neurohormonal blockade ther-
apy. If ACE-I were used alone, relative reduction
of mortality was 29% and beta-blockers alone dem-
onstrated 39% relative reduction in mortality [3].
There is no doubt that 100% of eligible patients
should be on these therapies. These and other data
are so convincing that in the US, both government
agencies and major insurance agencies, under pres-
sure from customers, are demanding hospital dis-
charge data providing performance measures of
physicians treating patients with heart failure. The
days of a high degree of autonomy with which phy-
sicians may practice are gone. These data are also
used to provide financial incentives to those institu-
tions that meet the 85% compliance witch ACE-I/
/ARB (angiotensin receptor blocker) therapy at dis-
charge (among other parameters). These data are
readily available for public on internet. Public de-
mand for quality care and public access to these data
has been a major driver in quality improvement in-
itiatives in hospitals in many areas of care includ-
ing heart failure. This trend demonstrated that hos-
pital-based systems can improve medical care and
education of hospitalized heart failure patients and
can accelerate use of evidence-based, guideline-rec-
ommended therapies by administering them before
hospital discharge.
Observation by Fedyk-Łukasik et al. [2] that
general practitioners are less comfortable with
treating patients with both ACE-I and beta-block-
ers is consistent with experience of others. Use of
ACE-I in patients before referral to heart failure
centers varies from 35% to 75%, depending on the
geographic region and the background of the refer-
ring physician in the US [4]. All guidelines have
delayed penetration into the market, despite the
frequently overwhelming evidence. In the same
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time this is greatly important issue since heart fail-
ure is traditionally treated by general practitioners
and with increasing numbers of patients, cardiologists
alone will not be able to provide care to this popula-
tion. Also in the US primary care physicians deliver
the majority of care to patients with heart failure and
only 17% of these patients ever see a cardiologist [5].
Fedyk-Lukasik’s data indicate significant gap
especially in use of beta-blockers in patients with
heart failure treated by general practitioners [2]. It
is thus important to stress the need for initiation of
these drugs prior to hospital discharge. This prac-
tice is known to increase their utilization and it has
also been demonstrated to be safe [6].
As if this was not challenging enough, device
therapy for HF, including implantable cardioverter
defibrillators and cardiac resynchronization thera-
py, has recently been demonstrated to also result
in substantial mortality reduction. Careful evalua-
tion of patients with heart failure with echocardi-
ography is becoming even more important to help
with patient selection. It is of note that only small
percentage (37%) of patients in Poland is evaluat-
ed by echocardiography as described by Fedyk-
-Łukasik et al. [2]. Since accurate evaluation of pa-
tients with heart failure is critical for the appropri-
ate selection and monitoring of therapy as well as
for the prevention of recurrent hospitalizations the
availability of this diagnostic modality should be
increased in Poland. Easy access to echocardiogra-
phy in the US was achieved in part by emergence
of support personnel such as echocardiography
technicians who are trained in performing echocar-
diographic examination, which later is interpreted
by a cardiologist. In the age of digital echocardiog-
raphy this approach allows for electronic transfer
of data from even remote sites and increases access
to expert echocardiographic interpretation for pa-
tients and their physicians, who otherwise would
have no available access to this diagnostic tool.
Further improvement in heart failure care rep-
resents significant challenge for the cardiology com-
munity in Poland. Development of HF disease man-
agement programs have been shown to improve HF
treatment, resulting in substantial reduction in hos-
pitalizations and mortality. These programs will
need to be developed in collaboration between car-
diologists with interest in management of heart fail-
ure and general practitioners. It was necessary in
the US to modify cardiology training programs to
accommodate the emergence of the new sub-spe-
cialty of heart failure physicians. At this time, no
established guidelines exist regarding the curricu-
lum of these programs or requirements that need
to be fulfilled by trainees and by training programs.
One year of training for internal medicine physicians
represents a practical approach, which should be
considered in view of the enormous needs of the
heart failure population. This training may result in
the relatively quick emergence of internal medicine
sub-specialists who will play a leadership role in the
primary care environment by providing quality,
evidence-based care to heart failure patients and
who will bridge the gap between primary and car-
diologic subspecialty care for patients with more
complex disease. The presence of primary care
physicians with special interest in heart failure may
increase interactions between primary care physi-
cians and cardiologists, with potentially significant
benefits to the patients. Even more important, this
group of primary care physicians will be exception-
ally positioned to champion heart failure prevention
issues — an important aspect of heart failure.
In conclusion, I congratulate Dr. Fedyk-Łukasik,
her co-authors and coworkers for undertaking this
difficult task of providing us with information re-
garding heart failure management in Poland [2].
References
1. American Heart Association. Heart Disease and
Stroke Statistics 2004 Update. American Heart
Association, Dallas, TX 2004.
2. Fedyk-Łukasik M, Zdrojewski T, Wizner B et al.
Heart failure management in Poland: the National
Cardiovascular Disease Prevention and Treatment
Program POLKARD, edition 2003–2005. Cardiol J,
2007; 14: 552–560.
3. Cohn JN, Carson PE, O’Connor C et al. Prognosis
and mechanism of death in treated heart failure: data
from the placebo arm of Val-HeFT. Congest Heart
Fail, 2006; 12: 127–131.
4. Stevenson LW, Massie BM, Francis GS et al. Opti-
mizing therapy for complex or refractory heart fail-
ure: a management algorithm. Am Heart J, 1998, 135
(6 Part 2): S293–S309.
5. O’Connell JB, Bristow MR. Economic impact of heart
failure in the United States: time for a different ap-
proach. J Heart Lung Transplant, 1994; 13 (suppl.):
107–112.
6. Gattis WA, O’Connor CM, Gallup DS et al. Predis-
chargwe initiation of carvedilol in patients hospitalized
for decompensated heart failure: Results of the Initi-
ation Management Predischarge: process for Assess-
ment of carvedilol Therapy in Heart failure
(IMPACT-HF) trial. J Am Coll Cardiol, 2004; 43: 1534.
